

*Cost and Utilization Analysis for
Rheumatoid Arthritis Treatments:
An Update for Managed Care*

This supplement to *The American Journal of Managed Care* contains information on economic issues associated with the treatment of rheumatoid arthritis. The supplement has been peer reviewed by an expert in the field.

Faculty

Joseph Doyle, RPh, MBA
Senior Manager
Health Economics and Outcomes Research
Aventis Pharmaceuticals Inc.
Bridgewater, New Jersey

Daniel M. Huse, MA
Chief Scientific Officer
PharMetrics, Inc.
Watertown, Massachusetts

Daniel A. Ollendorf, MPH
Director, Analytic and Consulting Services
PharMetrics, Inc.
Watertown, Massachusetts

Anna N. Peterson, BA
Programmer/Analyst
PharMetrics, Inc.
Watertown, Massachusetts

DISCLOSURE STATEMENT

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

This participant has declared the following affiliations with corporate organizations.

- **Joseph Doyle, RPh, MBA**
Employee of:
Aventis Pharmaceuticals Inc.

The participants listed below declare no financial arrangement or affiliation with any corporate organizations.

- **Daniel M. Huse, MA**
- **Daniel A. Ollendorf, MPH**
- **Anna N. Peterson, BA**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*Cost and Utilization Analysis for
Rheumatoid Arthritis Treatments:
An Update for Managed Care*

This program is supported by an educational grant from **Aventis Pharmaceuticals Inc.**



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.